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Abstract
Introduction Evidence-based recommendations can be made
with respect to many aspects of the acute management of the
bleeding trauma patient, which when implemented may lead to
improved patient outcomes.
Methods The multidisciplinary Task Force for Advanced
Bleeding Care in Trauma was formed in 2005 with the aim of
developing guidelines for the management of bleeding following
severe injury. Recommendations were formulated using a
nominal group process and the GRADE (Grading of
Recommendations Assessment, Development, and Evaluation)
hierarchy of evidence and were based on a systematic review of
published literature.
Results Key recommendations include the following: The time
elapsed between injury and operation should be minimised for
patients in need of urgent surgical bleeding control, and patients
presenting with haemorrhagic shock and an identified source of
bleeding should undergo immediate surgical bleeding control
unless initial resuscitation measures are successful. A damage
control surgical approach is essential in the severely injured
patient. Pelvic ring disruptions should be closed and stabilised,
followed by appropriate angiographic embolisation or surgical
bleeding control, including packing. Patients presenting with
haemorrhagic shock and an unidentified source of bleeding
should undergo immediate further assessment as appropriate
using focused sonography, computed tomography, serum
lactate, and/or base deficit measurements. This guideline also
ACS = American College of Surgeons; aPTT = activated partial thromboplastin time; CT = computerised tomography; DPL = diagnostic peritoneal 
lavage; FAST = focused abdominal sonography in trauma; FFP = fresh frozen plasma; GRADE = Grading of Recommendations Assessment, Devel-
opment, and Evaluation; Hb = haemoglobin; Hct = haematocrit; ICU = intensive care unit; KIU = kallikrein inhibitory units; MeSH = Medical Subject 
Heading; MSCT = multi-slice spiral computed tomography; NIH = National Institutes of Health; PCC = prothrombin complex concentrate; PEEP = 
positive end-expiratory pressure; PT = prothrombin time; RBC = red blood cell; RCT = randomised controlled trial; rFVIIa = recombinant activated 
coagulation factor VII; TRALI = transfusion-related acute lung injury; TRICC = Transfusion Requirements in Critical Care.Critical Care    Vol 11 No 1    Spahn et al.
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reviews appropriate physiological targets and suggested use
and dosing of blood products, pharmacological agents, and
coagulation factor replacement in the bleeding trauma patient.
Conclusion A multidisciplinary approach to the management of
the bleeding trauma patient will help create circumstances in
which optimal care can be provided. By their very nature, these
guidelines reflect the current state-of-the-art and will need to be
updated and revised as important new evidence becomes
available.
Introduction
Traumatic injury is the leading cause of death worldwide
among persons between 5 and 44 years of age [1] and
accounts for 10% of all deaths [2]. In 2002, 800,000 injury-
related deaths in Europe accounted for 8.3% of total deaths
[3]. Because trauma affects a disproportionate number of
young people, the burden to society in terms of lost productiv-
ity, premature death, and disability is considerable. Despite
improvements in trauma care, uncontrolled bleeding contrib-
utes to 30% to 40% of trauma-related deaths and is the lead-
ing cause of potentially preventable early in-hospital deaths [4-
6].
Resuscitation of the trauma patient with uncontrolled bleeding
requires the early identification of potential bleeding sources
followed by prompt action to minimise blood loss, to restore
tissue perfusion, and to achieve haemodynamic stability. Mas-
sive bleeding in trauma patients, defined here as the loss of
one blood volume within 24 hours or the loss of 0.5 blood vol-
umes within three hours, is often caused by a combination of
vascular injury and coagulopathy. Contributing factors to trau-
matic haemorrhage include both surgical and non-surgical
bleeding, prior medication, comorbidities, and acquired coag-
ulopathy [7].
Here, we describe early diagnostic measures to identify haem-
orrhage that should trigger surgical or radiological interven-
tions in most cases. Specific interventions to manage bleeding
associated with pelvic ring injuries and hypothermia are dis-
cussed, as well as recommendations for the optimal applica-
tion of fluid, pharmacological, blood product, and coagulation
factor therapy in trauma patients.
These guidelines for the management of the bleeding trauma
patient were developed by a multidisciplinary group of Euro-
pean experts and designated representatives from relevant
professional societies to guide the clinician in the early phases
of treatment. The recommendations presented here are based
on a critical survey of the published literature and were formu-
lated according to a consensus reached by the author group.
Many of the critical issues faced by the treating physician have
not been, and for ethical or practical reasons may never be,
addressed by prospective randomised clinical studies, and
therefore the formulation and grading of the recommendations
presented here are weighted to reflect both this reality and the
current state-of-the-art.
Materials and methods
These recommendations were formulated and graded accord-
ing the Grading of Recommendations Assessment, Develop-
ment, and Evaluation (GRADE) hierarchy of evidence outlined
by Guyatt and colleagues [8] and are summarised in Table 1.
Comprehensive computer database literature searches were
performed using the indexed online databases MEDLINE/
PubMed and the Cochrane Library. Lists of cited literature
within relevant articles were also screened. The primary inten-
tion of the review was to identify prospective randomised con-
trolled trials (RCTs) and non-randomised controlled trials,
existing systematic reviews, and guidelines. In the absence of
such evidence, case control studies, observational studies,
and case reports were considered.
Boolean operators and Medical Subject Heading (MeSH) the-
saurus keywords were applied as a standardised use of lan-
guage to unify differences in terminology into single concepts.
Appropriate MeSH headings and subheadings for each ques-
tion were selected and modified based on search results. The
scientific questions posed that led to each recommendation
and the MeSH headings applied to each search are listed in
Additional file 1. Searches were limited to English language
abstracts and human studies; gender and age were not lim-
ited. No time-period limits were imposed on searches unless
the search result exceeded 300 hits. Original publications
were evaluated for abstracts that were deemed relevant. In the
case of a guideline update, searches were limited to the time
period following the publication of the last version of the guide-
line. If an acceptable systematic review or meta-analysis was
identified, searches to update the data were typically limited to
the time period following the search cutoff date reported in the
review. Original publications were evaluated according to the
levels of evidence developed by the Oxford Centre for Evi-
dence-Based Medicine (Oxford, Oxfordshire, UK) [9].
The selection of the scientific inquiries to be addressed in the
guideline, screening, and grading of the literature to be
included and formulation of specific recommendations were
performed by members of the Task Force for Advanced Bleed-
ing Care in Trauma, a multidisciplinary, pan-European group of
experts with specialties in surgery, anaesthesia, emergency
medicine, intensive care medicine, and haematology. The core
group was formed in 2004 to produce educational material on
care of the bleeding trauma patient [10], on which a subse-
quent review article was based [11]. The Task Force con-
sisted of the core group, additional experts in haematology
and guideline development, and representatives of relevantAvailable online http://ccforum.com/content/11/1/R17
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European professional societies, including the European
Shock Society, the European Society for Anaesthesia, the
European Society for Emergency Medicine, the European
Society for Intensive Care Medicine, and the European
Trauma Society. The European Hematology Association
declined the invitation to send a representative to join the Task
Force. Task Force members participated in a workshop on the
critical appraisal of medical literature. The nominal group proc-
ess included four face-to-face meetings supplemented by sev-
eral Delphi rounds [12]. The guideline development group met
in June 2005 to define the scientific questions to be
addressed in the guideline and again in October 2005 to final-
ise the scientific scope of the guidelines. Selection, screening,
and grading of the literature and formulation of recommenda-
tions were accomplished in subcommittee groups consisting
of at least three members via electronic or telephone commu-
nication. After distribution of the recommendations to the
entire group, a further meeting of the Task Force was held in
April 2006 with the aim of reaching a consensus on the draft
recommendations from each subcommittee. After final refine-
ment of specific recommendations among committee
members, a subset of the Task Force met in July 2006 to final-
ise the manuscript document. The document was approved by
the endorsing organisations in September and October 2006.
An updated version of the guideline is anticipated in due time.
In the GRADE system for assessing each recommendation,
the letter attached to the grade of recommendation reflects
the degree of literature support for the recommendation,
whereas the number indicates the level of support for the rec-
ommendation assigned by the committee of experts. Recom-
mendations are grouped by category and somewhat
chronologically in the treatment decision-making process, but
not by priority or hierarchy.
Results
I. Initial resuscitation and prevention of further bleeding
Evidence to support the initial phase of resuscitation and pre-
vention of further bleeding is lacking, and there have been few
studies on the effect of coagulopathy on outcome. Patients
with a coagulopathic condition have worse outcomes than
patients of the same injury severity without a clotting distur-
bance [13,14], and patients with head injury also have worse
outcomes in association with a coagulopathy [15]; however,
contrary to popular belief, there is no evidence that patients
with head injury are more likely to develop a coagulopathy than
other severely injured patients [16].
Table 1
Grading of recommendations after Guyatt et al. [8]
Grade of recommendation Clarity of risk/benefit Quality of supporting evidence Implications
1A
Strong recommendation, high-quality 
evidence
Benefits clearly outweigh risk and 
burdens, or vice versa
Randomised controlled trials (RCTs) 
without important limitations or 
overwhelming evidence from 
observational studies
Strong recommendations, can apply to 
most patients in most circumstances 
without reservation
1B
Strong recommendation, moderate-
quality evidence
Benefits clearly outweigh risk and 
burdens, or vice versa
RCTs with important limitations 
(inconsistent results, methodological 
flaws, indirect, or imprecise) or 
exceptionally strong evidence from 
observational studies
Strong recommendations, can apply to 
most patients in most circumstances 
without reservation
1C
Strong recommendation, low-quality or 
very low-quality evidence
Benefits clearly outweigh risk and 
burdens, or vice versa
Observational studies or case series Strong recommendation but may 
change when higher-quality evidence 
becomes available
2A
Weak recommendation, high-quality 
evidence
Benefits closely balanced with risks 
and burden
RCTs without important limitations or 
overwhelming evidence from 
observational studies
Weak recommendation, best action 
may differ depending on circumstances 
or patients' or societal values
2B
Weak recommendation, moderate-
quality evidence
Benefits closely balanced with risks 
and burden
RCTs with important limitations 
(inconsistent results, methodological 
flaws, indirect, or imprecise) or 
exceptionally strong evidence from 
observational studies
Weak recommendation, best action 
may differ depending on circumstances 
or patients' or societal values
2C
Weak recommendation, low-quality or 
very low-quality evidence
Uncertainty in the estimates of benefits, 
risks, and burden; benefits, risk, and 
burden may be closely balanced
Observational studies or case series Very weak recommendation, other 
alternatives may be equally reasonableCritical Care    Vol 11 No 1    Spahn et al.
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There is no evidence as to whether the degree of initial bleed-
ing affects coagulopathy. Coagulopathy is predicted by a
systolic blood pressure of below 70 mm Hg [17], but this
could be either a direct effect of bleeding or an associated
effect of injury severity. There is no high-level scientific evi-
dence that the initial amount of bleeding affects the patient's
outcome; however, the experience of treating physicians is
that uncontrolled haemorrhage is associated with poor out-
come. Common experience is that wound compression pre-
vents bleeding, but it is not known whether this reduces the
incidence of coagulopathy. There is also no evidence that tells
us whether control of acid-base balance during initial resusci-
tation affects outcome.
There is evidence to support expedient care for patients fol-
lowing traumatic injury; however, no study has examined the
relationship between outcomes in patients transported to dif-
ferent types of hospital facilities and the amount of bleeding.
Pre-hospital bleeding not controlled by compression and
splintage requires rapid surgical or radiological intervention.
Recommendation 1
We recommend that the time elapsed between injury and
operation be minimised for patients in need of urgent surgical
bleeding control (grade 1A).
Rationale
Trauma patients in need of emergency surgery for ongoing
haemorrhage demonstrate better survival if the elapsed time
between the traumatic injury and admission to the operating
theatre is minimised [18-21]. Although there are no ran-
domised control studies to verify this statement, there are ret-
rospective studies that provide enough evidence for early
surgical intervention in these patients. This is particularly true
for patients who present in an exsanguinated state or in severe
haemorrhagic shock due to penetrating vascular injuries
[18,19]. In accordance with these observations, Blocksom
and colleagues [20] concluded that rapid resuscitation and
surgical control of haemorrhage is of utmost importance and
one of the prognostic determinants in a retrospective study on
duodenal injuries. A retrospective study by Ertel and col-
leagues [21] that included 80 polytrauma patients in extremis
or with persistent haemodynamic instability also favoured early
surgical intervention to stabilise a pelvic fracture or to surgi-
cally control bleeding.
In addition, studies of different trauma systems indirectly
emphasise the importance of minimising the time between ini-
tial care and surgery for those with signs of exsanguination or
ongoing severe haemorrhage. Hill and colleagues [22]
observed a significant decrease in mortality from shock by
introducing an educational program on trauma and by estab-
lishing a 60-minute emergency department time limit for
patients in a state of haemorrhagic shock. Others also stress
the importance of a well-functioning system capable of timely
control of haemorrhage in the exsanguinating or the severely
bleeding patient [23,24]. In a retrospective review of 537
deaths in the operation room, Hoyt and colleagues [25] drew
the conclusion that delayed transfer to the operating room was
a cause of death that could be avoided by shortening the time
required for diagnosis and resuscitation prior to surgery.
II. Diagnosis and monitoring of bleeding
Upon patient arrival in the emergency room, an initial clinical
assessment of the extent of bleeding should be employed to
identify patients at risk of coagulopathy.
Recommendation 2
We recommend that the extent of traumatic haemorrhage be
clinically assessed using a grading system such as that estab-
lished by the American College of Surgeons (ACS) (grade
1C).
Rationale
An evaluation of the mechanism of injury (for example, blunt
versus penetrating trauma) is a useful tool for determining
which patients are candidates for surgical bleeding control.
Table 2 summarises the four classes of physiological response
and clinical signs of bleeding as defined by the ACS [26]. This
type of grading system may be useful in the initial assessment
of bleeding. The initial assessment can also assist in
determining the next patient management goal to minimise
blood loss and achieve haemodynamic stability.
Recommendation 3
We do not suggest hyperventilation or the use of excessive
positive end-expiratory pressure (PEEP) when ventilating
severely hypovolaemic trauma patients (grade 2C).
Rationale
There is a tendency for rescue personnel to hyperventilate
patients during resuscitation [27,28], and hyperventilated
trauma patients appear to have increased mortality when com-
pared with non-hyperventilated patients [28]. The experimen-
tal correlates in animals in haemorrhagic shock may be an
increased cardiac output in hypoventilated pigs [29] and a
decrease in cardiac output due to 5 cm PEEP in rats [30]. In
contrast, the elimination of PEEP and, to an even greater
extent, negative expiratory pressure ventilation increases car-
diac output and survival of rats in haemorrhagic shock [30].
Recommendation 4
We recommend that patients presenting with haemorrhagic
shock and an identified source of bleeding undergo an imme-
diate bleeding control procedure unless initial resuscitation
measures are successful (grade 1B).
Rationale
The source of bleeding may be immediately obvious, and pen-
etrating injuries are more likely to require surgical bleedingAvailable online http://ccforum.com/content/11/1/R17
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control. In a retrospective study of 106 abdominal vascular
injuries, all 41 patients arriving in shock following gunshot
wounds were candidates for rapid transfer to the operating
theatre for surgical bleeding control [19]. A similar observation
in a study of 271 patients undergoing immediate laparotomy
for gunshot wounds indicates that these wounds combined
with signs of severe hypovolaemic shock specifically require
early surgical bleeding control. This observation is true to a
lesser extent for abdominal stab wounds [31]. Data on injuries
caused by penetrating metal fragments from explosives or
gunshot wounds in the Vietnam War confirm the need for early
surgical control when patients present in shock [18].
In blunt trauma, the mechanism of injury can determine to a
certain extent whether the patient in haemorrhagic shock will
be a candidate for surgical bleeding control. Only a few stud-
ies address the relationship between the mechanism of injury
and the risk of bleeding, however, and none of these publica-
tions is a randomised prospective trial of high evidence. We
have found no objective data describing the relationship
between the risk of bleeding and the mechanism of injury of
skeletal fractures in general or of long-bone fractures in
particular.
Traffic accidents are the leading cause of pelvic injury. Motor
vehicle crashes cause approximately 60% of pelvic fractures
followed by falls from great height (23%). Most of the remain-
der result from motorbike collisions and vehicle-pedestrian
accidents [32,33]. There is a correlation between 'unstable'
pelvic fractures and intra-abdominal injuries [32,34]. An asso-
ciation between major pelvic fractures and severe head inju-
ries, concomitant thoracic, abdominal, urological, and skeletal
injuries is also well described [32]. High-energy injuries pro-
duce greater damage to both the pelvis and organs. Patients
with high-energy injuries require more transfusion units, and
more than 75% have associated head, thorax, abdominal, or
genitourinary injuries [35]. It is well documented that 'unstable'
pelvic fractures are associated with massive haemorrhage
[34], and haemorrhage is the leading cause of death in
patients with major pelvic fractures. Pelvic fractures account
for 1% to 3% of all skeletal injuries. In patients with multiple
trauma, the incidence of pelvic fracture increases to as much
as 25% [33].
Recommendation 5
We recommend that patients presenting with haemorrhagic
shock and an unidentified source of bleeding undergo imme-
diate further assessment (grade 1B).
A patient in haemorrhagic shock with an unidentified source of
bleeding should undergo urgent clinical assessment of chest,
abdominal cavity, and pelvic ring stability using focused
abdominal sonography in trauma (FAST) assessment of thorax
and abdomen and/or computerised tomography (CT) exami-
nation in the shock room.
Sonography
Recommendation 6
We recommend early FAST for the detection of free fluid in
patients with suspected torso trauma (grade 1B).
Recommendation 7
We recommend that patients with significant free intra-
abdominal fluid according to sonography (FAST) and haemo-
dynamic instability undergo urgent surgery (grade 1C).
Rationale
Blunt abdominal trauma represents a major diagnostic chal-
lenge and an important source of internal bleeding. FAST has
been established as a rapid and non-invasive diagnostic
approach for detection of intra-abdominal free fluid in the
emergency room [36,37]. Large prospective observational
studies determined a high specificity (range 0.97 to 1.0) and
a high accuracy (range 0.92 to 0.99) but low sensitivity (range
0.56 to 0.71) of initial FAST examination for detecting intra-
abdominal injuries in adults and children [38-45]. Shackford
Table 2
American College of Surgeons Advanced Trauma Life Support classification of haemorrhage severity
Haemorrhage severity according to ACS/ATLS classificationa Class I Class II Class III Class IV
Blood loss (ml) <750 750–1,500 1,500–2,000 >2,000
Pulse rate (per minute) <100 >100 >120 >140
Blood pressure Normal Normal Decreased Decreased
Pulse pressure (mm Hg) Normal Decreased Decreased Decreased
Respiratory rate (per minute) 14–20 20–30 30–40 >40
Urine output (ml/hour) >30 20–30 5–15 Negligible
Central nervous system (mental status) Slightly 
anxious
Mildly anxious Anxious, 
confused
Lethargic
aValues are estimated for a 70-kg adult. Table reprinted with permission from the American College of Surgeons [26]. ACS/ATLS, American 
College of Surgeons/Advanced Trauma Life Support.Critical Care    Vol 11 No 1    Spahn et al.
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and colleagues [38] assessed the accuracy of FAST per-
formed by non-radiologist clinicians (that is, surgeons and
emergency physicians who were certified for FAST by defined
standards) for detecting a haemoperitoneum in 241 prospec-
tively investigated adult patients with blunt abdominal trauma
(except for n = 2 with penetrating injuries) during a four year
period. These findings were confirmed by Richards and co-
workers [39] in a four year prospective study of 3,264 adult
patients with blunt abdominal trauma. Similar conclusions
were drawn by the same group of investigators in a paediatric
population, based on a prospective study on 744 consecutive
children 16 years old or younger who underwent emergency
FAST for blunt abdominal trauma [40]. Liu and colleagues [41]
conducted a one year prospective comparison on the diag-
nostic accuracy of CT scan, diagnostic peritoneal lavage
(DPL), and sonography in 55 adult patients with blunt abdom-
inal trauma. The authors found a high sensitivity (0.92), specif-
icity (0.95), and accuracy (0.93) of initial FAST examination for
the detection of haemoperitoneum. Although CT scan and
DPL were shown to be more sensitive (1.0 for DPL, 0.97 for
CT) than sonography for detection of haemoperitoneum, these
diagnostic modalities are more time-consuming (CT and DPL)
and invasive (DPL) [41].
The hypotensive patient (systolic blood pressure below 90
mm Hg) presenting free intra-abdominal fluid according to
FAST is a potential candidate for early surgery if he or she can-
not be stabilised by initiated fluid resuscitation, according to a
retrospective study of 138 patients by Farahmand and col-
leagues [46]. A similar conclusion can be drawn from a pro-
spective blinded study of 400 hypotensive blunt trauma
victims (systolic blood pressure below 90 mm Hg) showing
that specific levels of intra-abdominal fluid detected by FAST
in these patients was an accurate indicator of the need for
urgent surgery [47]. In addition, a retrospective study by Rozy-
cki and colleagues [48] of 1,540 patients (1,227 blunt, 313
penetrating trauma) assessed with FAST as an early diagnos-
tic tool showed that the ultrasound examination had a sensitiv-
ity and specificity close to 100% when the patients were
hypotensive.
A number of patients who present free intra-abdominal fluid
according to FAST can safely undergo further investigation
with multi-slice spiral computed tomography (MSCT). Under
normal circumstances, adult patients need to be haemody-
namically stable when MSCT is performed outside of the
emergency room. In the retrospective study of 1,540 patients
(1,227 blunt, 313 penetrating trauma) who were assessed
early with FAST, a successful non-operative management was
achieved in 24 (48%) of the 50 patients who were normoten-
sive on admission and had true positive sonographic examina-
tions. These results justified an MSCT scan of the abdomen
rather than an immediate exploratory laparotomy [48]. In a
review article, Lindner and colleagues [49] also concluded
that the haemodynamically stable patient should undergo
MSCT scanning regardless of the findings from ultrasound or
clinical examination.
Computer tomography
Recommendation 8
We recommend that haemodynamically stable patients with
suspected head, chest, and/or abdominal bleeding following
high-energy injuries undergo further assessment using CT
(grade 1C).
Rationale
The increasing role of MSCT in the imaging concept of acute
trauma patients is well documented [50-55]. The integration of
modern MSCT scanners in the emergency room area allows
the immediate examination of trauma victims following admis-
sion [52,53].
Using modern 16-slice CT scanners, total whole-body scan-
ning time amounts to approximately 120 seconds. Sixty-four-
slice CT scanners may reduce scanning time to less than 30
seconds. In a retrospective study comparing 370 patients in
two groups, Weninger and colleagues [53] showed that the
full extent of injury was definitively diagnosed 12 ± 9 minutes
following application of the MSCT protocol. In the group of
conventionally diagnosed patients, definitive diagnosis was
possible after 41 ± 27 minutes. Faster diagnosis led to shorter
emergency room and operating room time and shorter inten-
sive care unit (ICU) stay [53]. Compared to MSCT, all tradi-
tional techniques of diagnostic and imaging evaluation have
some limitations. The diagnostic accuracy, safety, and effec-
tiveness of immediate MSCT is dependent on sophisticated
pre-hospital treatment by trained and experienced emergency
personnel and short transportation times [56,57].
If an MSCT is not available in the emergency room, the realisa-
tion of CT scanning implies transportation of the patient to the
CT room, and therefore the clinician must evaluate the implica-
tions and potential risks and benefits of the procedure.
According to established standards, such as those developed
by the ACS, only the haemodynamically stable patient should
be considered for CT scanning. During transport to the MSCT
and imaging, all vital signs should be closely monitored and
resuscitation measures continued.
For those patients in whom haemodynamic stability is ques-
tionable, imaging techniques such as ultrasound and chest
and pelvic radiography may be useful. Peritoneal lavage is
rarely indicated if ultrasound or CT is available [58]. Transfer
times to and from all forms of diagnostic imaging need to be
considered carefully in any patient who is haemodynamically
unstable. In addition to the initial clinical assessment, near-
patient testing results, including full blood count, haematocrit
(Hct), blood gases, and lactate, should be readily available
under ideal circumstances.Available online http://ccforum.com/content/11/1/R17
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Haematocrit
Recommendation 9
We do not recommend the use of single Hct measurements
as an isolated laboratory marker for bleeding (grade 1B).
Rationale
Hct measurements are part of the basic diagnostic work-up for
trauma patients. The diagnostic value of the Hct for detecting
trauma patients with severe injury and occult bleeding sources
has been a topic of debate in the past decade [59-61]. A major
limit of the diagnostic value is the confounding influence of
resuscitative measures on the Hct due to administration of
intravenous fluids and red cell concentrates [61-64]. A retro-
spective study of 524 trauma patients determined a low sen-
sitivity (0.5) of the initial Hct on admission for detecting those
patients with an extent of traumatic haemorrhage requiring sur-
gical intervention [61].
Two prospective observational diagnostic studies determined
the sensitivity of serial Hct measurements for detecting
patients with severe injury [59,60]. Paradis and colleagues
[59] found that the mean change in Hct between arrival and
15 minutes and between 15 and 30 minutes was not signifi-
cantly different between patients with serious injuries (n = 21)
compared to trauma patients without serious injuries (n = 39).
Whereas a decrease in Hct of more than or equal to 6.5% at
15 and 30 minutes had a high specificity (0.93 to 1.0) for a
serious injury, the sensitivity for detecting severely injured
patients was very low (0.13 to 0.16) [59]. The authors also
found that a normal Hct on admission did not preclude a sig-
nificant injury [59]. Zehtabchi and colleagues [60] expanded
the time window of serial Hct assessments to fourhours after
arrival. All trauma patients requiring a blood transfusion within
the first fourhours were excluded from the study. In the remain-
ing 494 patients, a decrease in Hct of more than 10%
between admission and fou hours was highly specific (0.92 to
0.96) for severe injury but was associated with a very low sen-
sitivity (0.09 to 0.27) for detecting patients with significant
injuries [60]. The limitation of the high specificity of the
decrease in Hct after fourhours in this study is that it included
only trauma patients who did not receive any blood transfu-
sions during the first fourhours [60]. In summary, decreasing
serial Hct measurements may reflect continued bleeding, but
the patient with significant bleeding may maintain his or her
serial Hct.
Serum lactate
Recommendation 10
We recommend serum lactate measurement as a sensitive
test to estimate and monitor the extent of bleeding and shock
(grade 1B).
Rationale
Serum lactate has been used as a diagnostic parameter and
prognostic marker of haemorrhagic shock since the 1960s
[65]. The amount of lactate produced by anaerobic glycolysis
is an indirect marker of oxygen debt, tissue hypoperfusion, and
the severity of haemorrhagic shock [66-69]. Vincent and col-
leagues [70] reported on the value of serial lactate measure-
ments in predicting survival in a prospective study on a
heterogenic group of 27 patients with circulatory shock. The
authors concluded that changes in lactate concentrations pro-
vide an early and objective evaluation of a patient's response
to therapy and suggested that repeated lactate determinations
represent a reliable prognostic index for patients with circula-
tory shock [70]. Abramson and colleagues [71] performed a
prospective observational study on patients with multiple
trauma to evaluate the correlation between lactate clearance
and survival. Patients who died within the first 48 hours (n =
25) were excluded from the study. The remaining 76 patients
were analysed with respect to the time of serum lactate nor-
malisation compared between survivors and non-survivors
who died after 48 hours [71]. Survival was 100% in those
patients in whom lactate levels returned to the normal range 
(≤ 2 mmol/l) within 24 hours. Survival decreased to 77.8% if
normalisation occurred within 48 hours and to 13.6% in those
patients in whom lactate levels were elevated above 2 mmol/l
for more than 48 hours [71]. These findings were confirmed in
a study on 129 trauma patients by Manikis and colleagues
[72]. The authors found that the initial lactate levels were
higher in non-survivors than in survivors and that the prolonged
time for normalisation of lactate levels of more than 24 hours
was associated with the development of post-traumatic organ
failure [72]. Together, both the initial serum lactate and serial
lactate levels are reliable indicators of morbidity and mortality
following trauma [71,72].
Base deficit
Recommendation 11
We recommend base deficit as a sensitive test to estimate and
monitor the extent of bleeding and shock (grade 1C).
Rationale
Base deficit values derived from arterial blood gas analysis
provide an indirect estimation of global tissue acidosis due to
impaired perfusion [66,68]. Siegel [73] demonstrated that the
initial base deficit represented an independent single predic-
tor of post-traumatic mortality in 185 patients with blunt liver
trauma. Two large retrospective studies on 3,791 [74] and
2,954 [75] trauma patients have strengthened the utility of the
initial base deficit as a sensitive diagnostic marker of the
degree and duration of inadequate perfusion and as a prog-
nostic parameter for post-traumatic complications and death.
Davis and colleagues [75] stratified the extent of base deficit
into three categories: mild (-3 to -5 mEq/l), moderate (-6 to -9
mEq/l), and severe (less than -10 mEq/l). Based on this strati-
fication, they established a significant correlation between the
admission base deficit and transfusion requirements within the
first 24 hours and the risk of post-traumatic organ failure or
death [75]. In a different retrospective study, the same groupCritical Care    Vol 11 No 1    Spahn et al.
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of authors showed that the base deficit is a better prognostic
marker of death than the pH in arterial blood gas analyses [76].
Furthermore, the base deficit was shown to represent a highly
sensitive marker for the severity of injury and the incidence of
post-traumatic death, particularly in trauma patients older than
55 years of age [77]. In paediatric patients, admission base
deficit was also shown to correlate significantly with the extent
of post-traumatic shock and mortality, as determined in a ret-
rospective study which included 65 critically injured children
and used a cutoff value of less than -5 mEq/l [78]. However, in
contrast to the data on lactate levels in haemorrhagic shock,
reliable large-scale prospective studies on the correlation
between base deficit and outcome are still lacking.
Although both the base deficit and serum lactate levels are
well correlated with shock and resuscitation, these two param-
eters do not strictly correlate with each other in severely
injured patients [79]. Therefore, the independent assessment
of both parameters is recommended for the evaluation of
shock in trauma patients [66,68,79,80]. Composite scores
that assess the likelihood of massive transfusion and that
include base deficit and other clinical parameters have been
developed but require further validation [80,81].
III. Rapid control of bleeding
Recommendation 12
We recommend that patients with pelvic ring disruption in
haemorrhagic shock undergo immediate pelvic ring closure
and stabilisation (grade 1B).
Recommendation 13
We recommend that patients with ongoing haemodynamic
instability despite adequate pelvic ring stabilisation receive
early angiographic embolisation or surgical bleeding control,
including packing (grade 1B).
Rationale
Markers of pelvic haemorrhage include anterior-posterior and
vertical shear deformations, CT 'blush' (active arterial extrava-
sation), bladder compression pressure, pelvic haematoma vol-
umes greater than 500 ml evident by CT, and ongoing
haemodynamic instability despite adequate fracture stabilisa-
tion [82-85]. Initial therapy of pelvic fractures includes control
of venous and/or canellous bone bleeding by pelvic closure
[86]. Some institutions use primarily external fixators to control
haemorrhage from pelvic fractures [82], but pelvic closure may
also be achieved using a bed sheet, pelvic binder, or a pelvic
C-clamp [86-90]. Although arterial haemorrhage from pelvic
fractures may be lethal, venous bleeding may be equally dev-
astating. Arterial embolisation appears to achieve its effect by
controlling the arterial bleeding and allowing the tamponade
effect of the haematoma to control venous bleeding [91,92].
Results of surgery to control pelvic haemorrhage via laparot-
omy have remained poor due to the existence of an extensive
collateral circulation. However, in suboptimal situations (for
example, when embolisation is not possible), extraperitoneal
packing of the pelvis may reduce the loss of blood. Extraperi-
toneal haemorrhage in patients with haemorrhagic shock and
pelvic ring disruption may be attributed to ruptured veins, frac-
ture surfaces, and/or arterial sources. The overall mortality rate
of patients with severe pelvic ring disruptions and haemody-
namic instability remains as high as 30% to 45% [93].
Angioembolisation is often applied in patients with ongoing
haemodynamic instability despite adequate fracture stabilisa-
tion and the exclusion of extra-pelvic sources of haemorrhage.
Repeat angiography may be of value in those selected patients
[86]. Patients who require embolisation tend to be older, have
a higher injury severity score, and are more likely to be coagu-
lopathic and haemodynamically unstable than patients who
not require embolisation [94].
Recommendation 14
We recommend that early bleeding control be achieved by
packing, direct surgical bleeding control, and the use of local
haemostatic procedures. In the exsanguinating patient, aortic
cross-clamping may be employed as an adjunct to achieve
bleeding control (grade 1C).
Rationale
The choice of thoracic or abdominal aortic clamping should be
determined according to the site of bleeding, available surgical
skill, and speed. The patient in haemorrhagic shock in whom
immediate aortic cross-clamping is warranted is characterised
by an injury to the torso and the severity of the blood loss and
shock. The hypotensive state will not respond to the intrave-
nous resuscitation and may lead to cardiac arrest. The cause
of injury is predominantly penetrating (for example, a gunshot
wound or a stab wound). Depending on the cause of injury, the
mortality rate in these situations is extremely high [18,19,95].
However, when the source of bleeding is intra-abdominal, tho-
racic aortic clamping combined with other measures for haem-
orrhage control can be life-salvaging in nearly one third of
patients, according to Millikan and Moore [96] and Cothren
and Moore [97]. It is unclear whether the thoracic aortic
clamping should be performed before or after the abdominal
incision [98]. No study has compared thoracic aortic clamping
above the diaphragm with abdominal aortic clamping just
below the diaphragm, although the latter method is favoured
by some surgeons [98].
The cross-clamping of the aorta should be considered as an
adjunct to other initial haemorrhage control measures such as
the evacuation of blood, direct surgical bleeding control, or
packing of bleeding sources [99]. When aortic clamping is
deemed necessary due to continuous bleeding or low blood
pressure, the prognosis is generally poor [100].Available online http://ccforum.com/content/11/1/R17
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Recommendation 15
We recommend that damage control surgery be employed in
the severely injured patient presenting with deep haemor-
rhagic shock, signs of ongoing bleeding, and coagulopathy.
Additional factors that should trigger a damage control
approach are hypothermia, acidosis, inaccessible major ana-
tomic injury, a need for time-consuming procedures, or con-
comitant major injury outside the abdomen (grade 1C).
Rationale
The severely injured patient arriving to the hospital with contin-
uous bleeding or deep haemorrhagic shock generally has a
poor chance of survival unless early control of bleeding, proper
resuscitation, and blood transfusion are achieved. This is par-
ticularly true for patients who present with uncontrolled bleed-
ing due to multiple penetrating injuries as well as patients with
multiple injuries and unstable pelvic fractures with ongoing
bleeding from fracture sites and retroperitoneal vessels. The
common denominator in these patients is the exhaustion of
physiological reserves with resulting profound acidosis, hypo-
thermia, and coagulopathy. In the trauma community, this is
also called the 'bloody vicious cycle' or the 'lethal triad.' In
1983, Stone and colleagues [101] described the techniques
of abbreviated laparotomy, packing to control haemorrhage
and of deferred definitive surgical repair until coagulation had
been established. Since then, a number of authors have
described the beneficial results of this concept, which is now
called 'damage control' [31,33,87,90,101-104]. Damage con-
trol consists of three components. The first component is an
abbreviated resuscitative laparotomy for control of bleeding,
the restitution of blood flow where necessary, and the control
of contamination. This should be achieved as quickly as possi-
ble without spending unnecessary time on traditional organ
repairs that can be deferred to a later phase. The abdomen is
packed and temporary abdominal closure is performed. The
second component is intensive care treatment, focused on
core rewarming, correction of the acid-base imbalance, and
coagulopathy as well as optimising the ventilation and the
haemodynamic status. Further diagnostic investigations are
also frequently performed during this phase. The third compo-
nent is the definitive surgical repair that is performed only
when target parameters have been achieved [99,105-107].
Despite the lack of controlled randomised studies comparing
damage control to traditional surgical management, a retro-
spective review by Stone and colleagues [101] presents data
in favour of damage control for the severely injured patient pre-
senting signs of coagulopathy during surgery. Rotondo and
colleagues [102] found similar results in a subgroup of
patients with major vascular injury and two or more visceral
injuries, and Carrillo and colleagues [103] demonstrated the
benefit of damage control in patients with iliac vessel injury. In
addition, a cumulative review of 961 patients treated with dam-
age control reported overall mortality and morbidity rates of
52% and 40%, respectively [106].
IV. Tissue oxygenation, type of fluid, and hypothermia
Recommendation 16
We suggest a target systolic blood pressure of 80 to 100 mm
Hg until major bleeding has been stopped in the initial phase
following trauma without brain injury (grade 2C).
Rationale
To maintain tissue oxygenation, traditional treatment of trauma
patients uses early and aggressive fluid administration to
restore blood volume. However, this approach may increase
the hydrostatic pressure on the wound and cause a dislodge-
ment of blood clots, a dilution of coagulation factors, and
undesirable cooling of the patient. The concept of low-volume
fluid resuscitation, so-called 'permissive hypotension,' avoids
the adverse effects of early aggressive resuscitation while
maintaining a level of tissue perfusion that, although lower than
normal, is adequate for short periods [108]. Its general effec-
tiveness remains to be confirmed in randomised clinical trials,
but studies have demonstrated increased survival when a low-
volume fluid resuscitation concept was used in penetrating
trauma [109,110]. In contrast, no significant difference was
found in patients with blunt trauma [111]. One study con-
cluded that mortality was higher after on-site resuscitation
compared with in-hospital resuscitation [112]. It seems that
greater increases in blood pressure are tolerated without
exacerbating haemorrhage when they are achieved gradually
and with a significant delay following the initial injury [113]. All
the same, a recent Cochrane systematic review concluded
that there is no evidence from randomised clinical trials for or
against early or larger volumes of intravenous fluids in uncon-
trolled haemorrhage [114]. The low-volume approach is con-
traindicated in traumatic brain injury and spinal injuries
because an adequate perfusion pressure is crucial to ensure
tissue oxygenation of the injured central nervous system. In
addition, the concept of permissive hypotension should be
considered carefully in the elderly patient and may be contrain-
dicated if the patient suffers from chronic arterial hypertension.
Red blood cell (RBC) transfusion enables the maintenance of
oxygen transport in some patients. Early signs of inadequate
circulation are relative tachycardia, relative hypotension, oxy-
gen extraction greater than 50%, and PvO2(mixed venous oxy-
gen pressure) of less than 32 mm Hg [115-117]. The depth of
shock, haemdoynamic response to resuscitation, and the rate
of actual blood loss in the acutely bleeding and haemodynam-
ically unstable patient may also be integrated into the indica-
tion for RBC transfusion. In general, RBC transfusion is
recommended to maintain haemoglobin (Hb) between 7 and
9 g/dl [118].
Recommendation 17
We suggest that crystalloids be applied initially to treat the
bleeding trauma patient. Colloids may be added within the
prescribed limits for each solution (grade 2C).Critical Care    Vol 11 No 1    Spahn et al.
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Rationale
It is still unclear which type of fluid should be employed in the
initial treatment of the bleeding trauma patient. Although sev-
eral meta-analyses have shown an increased risk of death in
patients treated with colloids compared with patients treated
with crystalloids [119-123] and three of these studies showed
that the effect was particularly significant in a trauma subgroup
[119,122,123], a more recent meta-analysis showed no differ-
ence in mortality between colloids and crystalloids [124].
Problems in evaluating and comparing the use of different
resuscitation fluids include the heterogeneity of populations
and therapy strategies, limited quality of analysed studies, mor-
tality not always being the primary outcome, and different
(often short) observation periods. It is therefore difficult to
reach a definitive conclusion as to the advantage of one type
of resuscitation fluid over the other. The SAFE (Saline versus
Albumin Fluid Evaluation) study compared 4% albumin with
0.9% sodium chloride in 6,997 ICU patients and showed that
albumin administration was not associated with worse out-
comes; however, there was a trend toward higher mortality in
the trauma subgroup that received albumin (p = 0.06) [125].
Promising results have been obtained with hypertonic solu-
tions. One study showed that use of hypertonic saline was
associated with lower intracranial pressure than with normal
saline in brain-injured patients [126], and a meta-analysis com-
paring hypertonic saline dextran with normal saline for resusci-
tation in hypotension from penetrating torso injuries showed
improved survival in the hypertonic saline dextran group when
surgery was required [127]. A clinical trial with brain injury
patients found that hypertonic saline reduced intracranial pres-
sure more effectively than dextran solution with 20% mannitol
[128]. However, Cooper and colleagues [129] found almost
no difference in neurological function six months after trau-
matic brain injury in patients who had received pre-hospital
hypertonic saline resuscitation compared to conventional fluid.
Recommendation 18
We recommend early application of measures to reduce heat
loss and warm the hypothermic patient in order to achieve and
maintain normothermia (grade 1C).
Rationale
Hypothermia, defined as a core body temperature of less than
35°C, is associated with acidosis, hypotension, and coagulop-
athy in severely injured patients. In a retrospective study with
122 patients, hypothermia was an ominous clinical sign,
accompanied by high mortality and blood loss [130]. The pro-
found clinical effects of hypothermia ultimately lead to higher
morbidity and mortality, and hypothermic patients require more
blood products [131].
Hypothermia is associated with an increased risk of severe
bleeding, and hypothermia in trauma patients represents an
independent risk factor for bleeding and death [132]. The
effects of hypothermia include altered platelet function,
impaired coagulation factor function (a 1°C decrease in tem-
perature is associated with a 10% decrease in function),
enzyme inhibition, and fibrinolysis [133,134]. Body tempera-
tures below 34°C compromise blood coagulation, but this has
been observed only when coagulation tests, prothrombin time
[PT] and activated partial thromboplastin time [aPTT] are car-
ried out at the low temperatures observed in patients with
hypothermia and not when assessed at 37°C, the temperature
typically used for such tests. Steps to prevent hypothermia
and the risk of hypothermia-induced coagulopathy include
removing wet clothing, covering the patient to avoid additional
heat loss, increasing the ambient temperature, forced air
warming, warm fluid therapy, and (in extreme cases) extracor-
poreal re-warming devices [135,136].
Animal and human studies of controlled hypothermia in haem-
orrhage have shown some positive results compared with nor-
mothermia [137,138]. In 2003, McIntyre and colleagues [139]
published a meta-analysis showing a beneficial effect on mor-
tality rates and neurological outcome when using mild hypo-
thermia in traumatic brain injury. In contrast, in 2004, one
meta-analysis analysed the effect of hypothermia in traumatic
brain injury using the results of eight studies with predefined
criteria for RCTs; no reduction in mortality rates and only a
slight benefit in neurological outcome could be demonstrated
[140]. These contradictory results may be due to the different
exclusion and inclusion criteria for the studies used for the
analysis. Henderson and colleagues [140] included two stud-
ies in which patients without increased intracranial pressure
were enrolled. Had these two studies been excluded from the
meta-analysis, a benefit with respect to improved neurological
outcome might have been demonstrated [141]. Moreover, the
studies included differed with respect to the speed of induc-
tion and duration of hypothermia, which may be very important
factors influencing the benefit of this treatment.
If mild hypothermia is applied in traumatic brain injury, cooling
should take place within the first 3 hours following injury and
be maintained for approximately 48 hours, rewarming should
last 24 hours, and the cerebral perfusion pressure should be
maintained above 50 mm Hg (70 mm Hg). Patients most likely
to benefit from hypothermia are those with a Glasgow Coma
Scale of between 4 and 7 at admission [142]. Possible side
effects are hypotension, hypovolaemia, electrolyte disorders,
insulin resistance, reduced insulin secretion, and increased
risk of infection [143]. Further studies are warranted to inves-
tigate the postulated benefit of hypothermia in traumatic brain
injury, taking these important factors into account.
V. Management of bleeding and coagulation
RBCs, fresh frozen plasma, and platelets
Recommendation 19
We recommend a target Hb of 7 to 9 g/dl (grade 1C).Available online http://ccforum.com/content/11/1/R17
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Rationale
There is experimental evidence that erythrocytes are involved
in the biochemical and functional responsiveness of activated
platelets, suggesting that erythrocytes contribute to haemos-
tasis. In addition to the rheological effect on the margination of
platelets, red cells support thrombin generation [144]. How-
ever, the optimal Hct or Hb concentration required to sustain
haemostasis in massively bleeding patients is unclear. Further
investigations into the role of the Hb concentration on hae-
mostasis in massively transfused patients are therefore
warranted.
The specific effect of the Hct on blood coagulation is largely
unknown [145]. An acute reduction of the Hct may result in an
increase in the bleeding time [146,147] with restoration upon
re-transfusion [146]. This may be related to the presence of
the enzyme elastase on the surface of RBC membranes, which
may activate coagulation factor IX, thereby triggering blood
coagulation [148,149]. However, a moderate reduction of the
Hct does not increase blood loss from a standard spleen injury
[147], and an isolated in vitro reduction of the Hct did not
compromise blood coagulation as assessed by thromboelas-
tography [150].
No prospective randomised trial has compared restrictive and
liberal transfusion regimens in trauma, but 203 trauma patients
from the Transfusion Requirements in Critical Care (TRICC)
trial [151] were re-analysed [118]. A restrictive transfusion
regimen (Hb transfusion trigger less than 7.0 g/dl) resulted in
fewer transfusions as compared with the liberal transfusion
regimen (Hb transfusion trigger less than 10 g/dl) and
appeared to be safe. However, no statistically significant ben-
efit in terms of multiple organ failure or post-traumatic infec-
tions was observed. It should be emphasised that this study
was neither designed nor powered to answer these questions
with precision. In addition, it cannot be ruled out that the
number of RBC units transfused reflects merely the severity of
injury. Therefore, the observed correlation between numbers
of RBC units transfused and multiple organ failure [152] may
reflect a correlation between the severity of injury and multiple
organ failure. Adequately powered studies similar to the
TRICC trial are therefore urgently needed in post-traumatic
patients.
Despite the lack of high-level scientific evidence for a specific
Hb transfusion trigger in patients with traumatic brain injury,
these patients are currently transfused in many centres to
achieve an Hb of approximately 10 g/dl [153]. This may be jus-
tified by the recent finding that increasing the Hb from 8.7 to
10.2 g/dl improved local cerebral oxygenation [154]. It
remains unclear, however, whether this practice will result in
an improved neurological outcome. Although the lowest Hct
was correlated with adverse neurological outcome, RBC
transfusions were equally found to be an independent factor
for adverse neurological outcome in a recent retrospective
study [155]. Interestingly, the number of days with an Hct
below 30% was found to be correlated with an improved neu-
rological outcome. Therefore, the authors suggest that
patients with severe traumatic brain injury should not have an
Hb transfusion threshold different than that of other critically ill
patients [155].
Recommendation 20
We recommend treatment with thawed fresh frozen plasma
(FFP) in patients with massive bleeding or significant bleeding
complicated by coagulopathy (PT or aPTT more than 1.5 times
control). The initial recommended dose is 10 to 15 ml/kg, but
further doses may be required (grade 1C).
Rationale
The clinical efficacy of FFP is largely unproven [156]. Never-
theless, most guidelines recommend the use of FFP either in
massive bleeding or in significant bleeding complicated by
coagulopathy (PT or aPTT more than 1.5 times control)
[7,157,158]. Patients treated with oral anticoagulants (vitamin
K antagonists) present a particular challenge, and thawed FFP
is recommended [158] only when prothrombin complex con-
centrate (PCC) is not available [157]. The most frequently rec-
ommended dose is 10 to 15 ml/kg [157,158], but further
doses may be required [159].
As with all products derived from human blood, the risks asso-
ciated with FFP treatment include circulatory overload, ABO
incompatibility, transmission of infectious diseases (including
the prion diseases), mild allergic reactions, and (particularly)
transfusion-related acute lung injury (TRALI) [157,160,161].
FFP and platelet concentrates appear to be the most fre-
quently implicated blood products in TRALI [160-163].
Although the formal link between the administration of FFP,
control of bleeding, and an eventual improvement in the out-
come of bleeding patients is lacking, most experts would
agree that FFP treatment is beneficial in patients with massive
bleeding or significant bleeding complicated by coagulopathy.
Recommendation 21
We recommend that platelets be administered to maintain a
platelet count above 50 × 109/l (grade 1C). We suggest main-
tenance of a platelet count above 100 × 109/l in patients with
multiple trauma who are severely bleeding or have traumatic
brain injury (grade 2C). We suggest an initial dose of 4 to 8
platelet concentrates or one aphaeresis pack (grade 2C).
Rationale
In medical conditions leading to thrombocytopaenia, haemor-
rhage does not often occur until the platelet count falls to less
than 50 × 109/l, and platelet function decreases exponentially
below this point [164-167]. There is no direct evidence to sup-
port a particular platelet transfusion threshold in the trauma
patient. A consensus development conference sponsored by
the National Institutes of Health (NIH) (Bethesda, MD, USA) inCritical Care    Vol 11 No 1    Spahn et al.
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1986 determined that bleeding is unlikely to be caused by
thrombocytopaenia at platelet counts of 50 × 109/l or greater
and agreed that platelet transfusion is appropriate to prevent
or control bleeding associated with deficiencies in platelet
number or function [168,169]. The NIH consensus did not
consider trauma, but it seems reasonable to recommend that
a platelet count of at least 50 × 109/l be maintained following
injury.
An argument can be made for maintaining a higher level of
platelets, perhaps up to 100 × 109/l, following injury. If a
patient has increased fibrin degradation products (for exam-
ple, in patients with massive bleeding), disseminated intravas-
cular coagulation, or hyperfibrinolysis, this will interfere with
platelet function and a higher threshold of 75 × 109/l has been
suggested by consensus groups [170,171]. Transfusion
threshold levels of up to 100 × 109/l have been suggested for
treatment of severe brain injury and massive haemorrhage, but
the evidence for the higher threshold is weak [170,171].
When platelet transfusion was introduced in the 1950s, no
clinical trials were employed to assess the utility of platelet
therapy compared to placebo, and such trials today might be
considered unethical. The appropriate dose of platelets is
therefore uncertain. Platelet concentrate produced from a unit
of whole blood contains 7.5 × 1010 platelets on average and
should increase the platelet count by 5 to 10 × 109/l in a 70-
kg recipient. Aphaeresis platelet concentrates generally con-
tain approximately 3 to 6 × 1011 platelets, depending on local
collection practice, and physicians should be cognizant of the
doses provided locally. A pool of 4 to 8 platelet concentrates
or a single-donor aphaeresis unit is usually sufficient to provide
haemostasis in a thrombocytopaenic, bleeding patient.
If required, the dose of platelets (× 109) can be calculated in
more detail from the desired platelet increment, the patient's
blood volume in litres (estimated by multiplying the patient's
body surface area by 2.5, or 70 ml/kg in an adult), and a cor-
rection factor of 0.67 to allow for pooling of approximately
33% of transfused platelets in the spleen.
Recommendation 22
We recommend treatment with fibrinogen concentrate or cry-
oprecipitate if significant bleeding is accompanied by a
plasma fibrinogen level of less than 1 g/l. We suggest an initial
fibrinogen concentrate dose of 3 to 4 g or 50 mg/kg of cryo-
precipitate, which is approximately equivalent to 15 to 20 units
in a 70-kg adult. Repeat doses should be guided by laboratory
assessment of fibrinogen levels (grade 1C).
Rationale
Cryoprecipitate or fibrinogen is used for the correction of both
inherited and acquired hypofibrinogenaemia. Their use is
based on the assumptions that low fibrinogen levels are asso-
ciated with a risk of bleeding and that the achievement of
higher levels of fibrinogen decreases that risk. The evidence
for the clinical efficacy of cryoprecipitate and fibrinogen in
trauma patients is limited; no clinical randomised studies have
been performed to determine whether the administration of
cryoprecipitate or fibrinogen improves clinical outcome in
severely bleeding trauma patients. Only indirect observational
studies are available, but this evidence suggests that clinically
significant bleeding decreases in a variety of clinical scenarios
following treatment with both agents. Hypofibrinogenaemia
responds well to treatment with cryoprecipitate concentrate
[172]. Administration of fibrinogen was associated with bleed-
ing control in patients with generalised, mostly traumatic,
bleeding [173]. Administration of 4 g of fibrinogen raised
fibrinogen levels from 0.1 to 1 g/l, and bleeding control was
achieved in patients with bleeding associated with uterine rup-
ture and abortion [174]. A few observational studies report the
successful use of fibrinogen in patients with congenital afibrin-
ogenaemia [175-177]. The optimal initial dose has not been
defined, and regional differences in cryoprecipitate and fibrin-
ogen preparations exist, but available evidence suggests that
an initial dose of cryoprecipitate or fibrinogen that raises fibrin-
ogen plasma level above 1 g/l will provide sufficient haemos-
tasis [174,176,178].
There are no specific risks related to administration of fibrino-
gen or cryoprecipitate other than the risks associated with
other blood components and the increased risk associated
with pooled versus single-donor blood products. Fibrinogen or
cryoprecipitate can have unpredictable adverse effects. Of
particular concern are allergic reactions and anaphylaxis.
There are no reported specific adverse events related to
administration of fibrinogen or cryoprecipitate in patients with
hypofibrinogenaemia.
Pharmacological agents
A large body of evidence supports the use of antifibrinolytic
agents for the management of bleeding in elective surgery and
cardiac surgery patients. For the purpose of these guidelines,
we have assumed that these effects are transferable to trauma
patients, and our recommendation is based upon this
unproven assumption.
Recommendation 23
We suggest that antifibrinolytic agents be considered in the
treatment of the bleeding trauma patient. Suggested dosages
are tranexamic acid (trans-4-aminomethylcyclohexane-1-car-
boxylic acid) 10 to 15 mg/kg followed by an infusion of 1 to 5
mg/kg per hour, ε-aminocaproic acid 100 to 150 mg/kg fol-
lowed by 15 mg/kg per hour, or (after a test dose) aprotinin 2
million kallikrein inhibitory units (KIU) immediately followed by
500,000 KIU/hour in an intravenous infusion. Antifibrinolytic
therapy should be stopped once bleeding has been ade-
quately controlled (grade 2C).Available online http://ccforum.com/content/11/1/R17
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Rationale
Tranexamic acid is a synthetic lysine analogue that is a com-
petitive inhibitor of plasmin and plasminogen. Tranexamic acid
is distributed throughout all tissues and the plasma half-life is
120 minutes. There is large variation in the dose employed. In
vitro  studies have suggested that a dose of 10 μg/ml is
required to inhibit fibrinolysis [179]. Studies of plasma levels
[180] confirmed that the Horrow regimen (10 mg/kg followed
by 1 mg/kg per hour) [181], shown to reduce blood loss in car-
diac surgery, attained these levels. Other studies have used
boluses of up to 5 g per patient with no ill effect [182].
ε-Aminocaproic acid is also a synthetic lysine analogue that
has a potency 10-fold weaker than that of tranexamic acid. It
is therefore administered in a loading dose of 150 mg/kg fol-
lowed by a continuous infusion of 15 mg/hour. The initial elim-
ination half-life is 60 to 75 minutes and it must therefore be
administered by continuous infusion in order to maintain ther-
apeutic drug levels until the bleeding risk has diminished.
Aprotinin is a broad-spectrum serine protease inhibitor iso-
lated from bovine lung and forms irreversible inhibitory com-
plexes with a number of serine proteases. In particular, it is a
powerful antiplasmin agent, and the initial elimination of apro-
tinin is 1.5 to 2 hours [183]. The 'high-dose' regimen [184] (2
MKIU to patient and cardiopulmonary bypass prime and an
infusion of 500,000 KIU/hour) has been shown to reduce peri-
operative bleeding in open cardiac surgery. However, lower
doses do produce adequate antiplasmin effects. A dose of 2
M units is approved for the treatment of hyperfibrinolysis.
The clear efficacy of antifibrinolytic agents in elective surgery
and especially in cardiac surgery has been shown in numerous
clinical trials [184,185]. A larger number of trials to evaluate
the efficacy of aprotinin have been published than assess-
ments of lysine analogue efficacy. It may be possible to extrap-
olate the benefits of antifibrinolytic agents to bleeding
secondary to trauma, but this assumption is not backed by any
published data that suggest that the haemostatic response to
trauma is similar to the haemostatic response to elective sur-
gery. There is insufficient evidence from RCTs of antifibrino-
lytic agents in trauma patients to either support or refute a
clinically important treatment effect. Further RCTs of antifibri-
nolytic agents in trauma patients are required [186]. The effi-
cacy of tranexamic acid in trauma will be assessed by the
ongoing CRASH (Clinical Randomisation of an Antifibrinolytic
in Significant Haemorrhage) II study, in which 20,000 trauma
patients worldwide are being randomly assigned to 1 g of tran-
examic acid for a period of 10 minutes followed by 1 g infused
for a period of 8 hours [187].
The risk of precipitated thrombosis with the use of antifibrino-
lytic agents has been of major theoretical concern; however,
the Cochrane review of antifibrinolytics cites studies that
included more than 8,000 patients and demonstrated no
increased risk of either arterial or venous thrombotic events
[188]. All antifibrinolytics are renally excreted and accumulate
in individuals with renal failure, and therefore dosage should
be reduced in patients with renal failure. In practice, mild
degrees of renal failure do not seem to affect outcome.
Because aprotinin is a bovine protein with an associated risk
of anaphylaxis, a test dose must be given. After high-dose
aprotinin, as many as 50% of patients develop specific immu-
noglobulin G antibodies within three months of exposure. The
manufacturer (Bayer Pharmaceuticals Corporation, West
Haven, CT, USA) estimates a 0.5% overall risk of anaphylactic
reactions following aprotinin treatment, which may increase to
6% to 9% following re-exposure [183].
An open study by Mangano and colleagues [189] suggested
that aprotinin usage in cardiac surgery was associated with an
increased risk of myocardial infarction, stroke, and renal failure.
A further publication cited an increased risk of renal problems
in patients receiving aprotinin compared to tranexamic acid
[190]. Because the study of Mangano and colleagues [189]
was open, it remains unclear whether sicker patients in the
study may have preferentially received aprotinin. A blinded
comparative study of aprotinin versus tranexamic acid versus
ε-aminocaproic acid [191] which aims to recruit 3,000
patients will assess safety and efficacy issues in cardiac sur-
gery. At present, in light of the current US Food and Drug
Administration warning against the use of aprotinin [192], the
greater cost associated with aprotinin use, and the need to
give a test dose (often impractical in an emergency situation),
we favour the use of tranexamic acid or ε-aminocaproic acid in
trauma patients.
Factor replacement
Recommendation 24
We suggest that the use of recombinant activated coagulation
factor VII (rFVIIa) be considered if major bleeding in blunt
trauma persists despite standard attempts to control bleeding
and best-practice use of blood components. We suggest an
initial dose of 200 μg/kg followed by two doses of 100 μg/kg
administered at 1 and 3 hours following the first dose (grade
2C).
Rationale
rFVIIa is not a first-line treatment for bleeding and will be effec-
tive only once sources of major bleeding have been controlled.
Once major bleeding from damaged vessels has been
stopped, rFVIIa may be helpful to induce coagulation in areas
of diffuse small vessel coagulopathic bleeding. rFVIIa should
be considered only if first-line treatment with a combination of
surgical approaches, best-practice use of blood products
(RBCs, platelets, FFP, and cryoprecipitate/fibrinogen resulting
in Hctabove 24%, plateletsabove 50,000 × 109/l, and fibrino-
genabove 0.5 to 1.0 g/l) and correction of severe acidosis,
severe hypothermia, and hypocalcaemia (resulting in pHaboveCritical Care    Vol 11 No 1    Spahn et al.
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7.20, temperatureabove 32°C, and ionised Ca++above 0.8
mmol/l, respectively) fail to control bleeding. Because rFVIIa
acts on the patient's own clotting system, a sufficient number
of platelets are needed to allow a thrombin burst to be induced
by the pharmacological, supraphysiological doses of rFVIIa
through direct binding to activated platelets [193,194].
Reduction in platelet count may lead to impaired thrombin
generation [195]. Moreover, fibrinogen is required to ensure
formation of a stable clot [158,196]. A recent study showed
that a pH below 7.20 substantially reduced rFVIIa activity but
that a temperature above 32°C only slightly improved rFVIIa
activity [197]. Independent of rFVIIa activity, however, pH and
body temperature should be restored as near to physiological
levels as possible since even small reductions in pH and tem-
perature may result in slower coagulation enzyme kinetics
[133,134,198]. Moreover, hypocalcaemia is frequently
present in severely injured patients [199] and may require the
administration of intravenous calcium with frequent ionised
serum calcium measurement [200].
A number of case studies and case series have reported that
treatment with rFVIIa can be beneficial in the treatment of
coagulopathic bleeding following trauma [201-204]. A
recently published multi-centre, randomised, double-blind, pla-
cebo-controlled study examined the efficacy of rFVIIa in
patients with blunt or penetrating trauma [205]. Patients were
randomly assigned to receive either three doses of rFVIIa
(200, 100, and 100 μg/kg) or placebo after they had received
6 units of RBCs. The first dose of their assigned medication
was administered after transfusion of a further 2 units of RBCs
(8 units in total), and a second and third dose were adminis-
tered 1 and 3 hours later. Treatment with rFVIIa in blunt trauma
produced a significant reduction in RBC transfusion require-
ments and the need for massive transfusions (>20 units of
RBCs) in patients with blunt trauma surviving for more than 48
hours and also significantly reduced the incidence of acute
respiratory distress syndrome in all patients with blunt trauma.
In contrast, no significant effects were observed on RBC
transfusion requirements in the penetrating trauma patients in
this study, although trends toward reduced RBC requirements
and fewer massive transfusions were observed. Therefore, no
recommendation to use the drug in this group can be made.
The required dose(s) of rFVIIa is still under debate. Whereas
the above dosing recommendation is based on the only pub-
lished RCT available in trauma patients and is also recom-
mended by a group of European experts [206], Israeli
guidelines based on findings from a case series of 36 patients
who received rFVIIa on a compassionate-use basis in Israel
[201] propose an initial dose of 120 μg/kg (between 100 and
140 μg/kg) and (if required) a second and third dose. Further
support for the dose regimen recommended here comes from
pharmacokinetic modelling techniques, which have shown
that the dose regimen for rFVIIa treatment used in the above-
cited RCT is capable of providing adequate plasma levels of
drug to support haemostasis [207]. If rFVIIa is administered,
the patient's next of kin should be informed that rFVIIa is being
used outside the currently approved indications (off-label use),
especially since the use of rFVIIa may increase the risk of
thromboembolic complications [208].
Recommendation 25
We recommend the use of PCC according to the manufac-
turer's instructions only for the emergency reversal of vitamin
K-dependent oral anticoagulants (grade 1C).
Rationale
Despite the common use of PCC, there is no clear indication
for its use in bleeding non-haemophilia patients. The evidence
of clinical efficacy of PCC in patients without haemophilia is
limited, and no clinical randomised studies have been per-
formed to determine whether administration of PCC improves
clinical outcome in severely bleeding trauma patients. PCC
has been used to control bleeding in haemophilia patients
[209-211] or to reverse the effect of oral anticoagulant agents
[212,213]. The American Society of Anesthesiology recom-
mends the use of PCC in patients with clinical coagulopathy
and prolonged PT more than 1.5 times normal [158]. Because
there are variations in the production of PCC, the dosage
should be determined according to the instructions of the indi-
vidual manufacturer [214].
Administration of PCC may carry the risk of venous and arterial
thrombosis or disseminated intravascular coagulation
[215,216]; however, the type of surgery has no influence on
the type and severity of these complications [217]. Decreased
clearance of activated clotting factor complexes increases the
likelihood of these complications in patients with liver disease
[218].
Recommendation 26
We do not recommend the use of antithrombin III in the treat-
ment of the bleeding trauma patient (grade 1C).
Antithrombin concentrates are indicated in inherited and
acquired antithrombin deficiency. Although antithrombin defi-
ciency does occur in consumptive coagulopathy, this is not an
isolated condition; all coagulation factors and physiological
anticoagulants undergo consumption under these circum-
stances. The best replacement therapy is FFP. Clinical studies
of antithrombin concentrate in severe blunt trauma and in crit-
ical care have shown no benefit [219,220].
Discussion
These guidelines for the management of the bleeding trauma
patient are based on a critical appraisal of the published liter-
ature and were formulated according to a consensus reached
by the author group and the professional societies involved.
We have attempted in an evidence-based manner to address
a number of critical issues faced by the treating physician con-Available online http://ccforum.com/content/11/1/R17
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fronted with a critically bleeding patient. Figure 1 graphically
summarises the recommendations included in this guideline.
Unfortunately in emergency medicine, a number of pivotal
issues have not been, and due to ethical and practical consid-
erations may never be, addressed in randomised clinical trials.
This reality renders the need for best-practice guidelines even
more acute.
Although the emphasis in these guidelines has been on the
management of critical bleeding in the trauma patient, the high
risk of venous thromboembolism in trauma patients should
always be kept in mind and thromboprophylactic treatment
considered once bleeding has been controlled [221]. In addi-
tion, a conscious decision was made to exclude animal studies
from the literature reviewed for the development of these
guidelines. Because no animal model has accurately mimicked
the human coagulation system, RCTs in humans provide the
strongest evidence for the management of bleeding in
humans.
We have made an effort to consider a number of specific
patient subgroups that may require treatment that has been
adapted to their physiological condition. There is very little
evidence, however, to support specific recommendations for
these special patient groups. The physiology of elderly
patients with respect to coagulopathy is probably not different
than that of younger adults; however, the bleeding patient who
has been treated with an anticoagulant or an antiplatelet agent
may present with a greater risk of coagulopathic bleeding. We
have also considered the management of bleeding following
injury in children. A more conservative approach to the surgical
management of bleeding in children is generally taken, and
there is some evidence that commonly quoted age-related
physiological norms are not applicable to the injured child.
There is little evidence, however, for specific differences in
bleeding and coagulation management in children; therefore,
we suggest that these guidelines be applied to both adults
and children until research data that are more specific become
available.
Figure 1
Flowchart of treatment aspects for the bleeding trauma patient which are discussed in this guideline Flowchart of treatment aspects for the bleeding trauma patient which are discussed in this guideline. aPTT, activated partial thromboplastin time; AT 
III, antithrombin III; CT, computerised tomography; FAST, focused abdominal sonography in trauma; FFP, fresh frozen plasma; Hb, haemoglobin; KIU, 
kallikrein inhibitory units; PCC, prothrombin complex concentrate; PT, prothrombin time; RBC, red blood cell; rFVIIa, recombinant activated coagula-
tion factor VII.
R5
Further assessment
***
Patients presenting with haemorrhagic 
shock and an unidentified source of 
bleeding should undergo immediate 
further assessment. 
I.
Initial resuscitation and prevention of 
further bleeding
II.
Diagnosis and monitoring of 
bleeding
III.
Rapid control of bleeding
V.
Management of bleeding and 
coagulation
IV.
Tissue oxygenation, fluid and 
hypothermia
R3
Ventilation
***
Severely hypovolaemic trauma patients 
may not be hyperventilated or subjected to 
excessive positive end-expiratory pressure. 
R2
Initial assessment
***
The extent of traumatic haemorrhage 
should be clinically assessed using an 
established grading system. 
R1
Minimal elapsed time
***
The time elapsed between injury and 
operation should be minimised. 
Surgical intervention
R13
Angiographic embolisation or surgery
***
Patients with ongoing haemodynamic instability despite 
adequate pelvic ring stabilisation should receive early 
angiographic embolisation or surgical bleeding control, 
including packing. 
R12
Pelvic ring closure & stabilisation
***
Patients with pelvic ring disruption in 
haemorrhagic shock should undergo immediate 
pelvic ring closure and stabilisation. 
R14
Cross clamping
***
Early bleeding control should be achieved using 
packing, direct surgical bleeding control and local 
haemostatic procedures; aortic cross clamping may 
be employed as an adjunct bleeding control in the 
exsanguinating patient.
R15
Damage control surgery
***
Damage control surgery should be employed in 
the severely injured patient presenting with deep 
hemorrhagic shock, signs of ongoing bleeding 
and coagulopathy, hypothermia, acidosis, 
inaccessible major anatomic injury, a need for 
time-consuming procedures or concomitant major 
injury outside the abdomen. 
Coagulation management
R23
Antifibrinolytic agents
***
Antifibrinolytic agents may be considered in the 
treatment of the bleeding trauma patient at the following 
dosages: tranexamic acid 10–15 mg/kg followed by an 
infusion of 1–5 mg/kg/h; İ-aminocaproic acid 100–
150 mg/kg followed by 15 mg/kg/h; or, after a test dose, 
aprotinin 2 million KIU immediately followed by 
500,000 KIU/h in an intravenous infusion. 
Antifibrinolytic therapy should be stopped once 
bleeding has been adequately controlled.
R21
Platelets
***
Platelets should be administered to maintain a platelet 
count above 50×10
9/l. A platelet count above 100×10
9/l
in patients with multiple trauma who are severely 
bleeding or have traumatic brain injury may be 
maintained with an initial dose of 4–8 platelet 
concentrates or one apheresis pack.
R26
AT III
***
Antithrombin III should not be employed in the 
treatment of the bleeding trauma patient.
R22
Fibrinogen or cryoprecipitate
***
Treatment with fibrinogen concentrate or 
cryoprecipitate should be employed if significant 
bleeding is accompanied by a plasma fibrinogen level 
less than 1 g/l at an initial fibrinogen concentrate 
dose of 3–4 g or 50 mg/kg of cryoprecipitate 
approximately equivalent to 15–20 units in a 70 kg 
adult. Repeat doses should be guided by laboratory 
assessment of fibrinogen levels.
R20
FFP
***
Patients with massive bleeding or significant bleeding 
complicated by coagulopathy (PT or aPTT >1.5 times 
control) should be treated with thawed FFP at an initial 
dose of 10–15 ml/kg; further doses may be required. 
R24
rFVIIa
***
Treatment with rFVIIa may be considered if major 
bleeding in blunt trauma persists despite standard 
attempts to control bleeding and best practice use of 
blood components at an initial dose of 200 μg/kg 
followed by two 100 μg/kg doses administered at 1 and 
3 h following the first dose.
R25
PCC
***
Treatment with prothrombin complex concentrate 
according to the manufacturer’s instructions should be 
employed only for the emergency reversal of vitamin K-
dependent oral anticoagulants.
Resuscitation
R17
Fluid therapy
***
Crystalloids may be applied initially to treat the 
bleeding trauma patient. Colloids may be added within 
the prescribed limits for each solution. 
R16
Volume replacement
***
A target systolic blood pressure of 80–100 mmHg may 
be appropriate until major bleeding has been stopped 
in the initial phase following trauma without brain injury. 
R18
Normothermia
Early application of measures to reduce heat loss and 
warm the hypothermic patient should be employed to 
achieve and maintain normothermia. 
R19
RBCs
***
Treatment should aim to achieve a target Hb of 7–9 g/dl. 
Extent of bleeding
R10
Serum lactate
***
Serum lactate should be employed to 
estimate and monitor the extent of 
bleeding and shock. 
R8
Computed tomography
***
Haemodynamically stable patients with 
suspected head, chest and/or abdominal 
bleeding following high-energy injuries should 
undergo further assessment using CT. 
Source of bleeding
R7
Sonography
***
Patients with significant free 
intraabdominal fluid and haemodynamic
instability should undergo urgent surgery. 
R6
Sonography
***
Early focused sonography (FAST) should 
be employed for the detection of free fluid 
in patients with suspected torso trauma. 
R9
Haematocrit
***
Single haematocrit measurements 
should not be employed as an isolated 
laboratory marker for bleeding. 
R11
Base deficit
***
Base deficit should be employed to 
estimate and monitor the extent of 
bleeding and shock. 
R4
Immediate intervention
***
Patients presenting with haemorrhagic 
shock and an identified source of bleeding 
should undergo an immediate bleeding 
control procedure unless initial 
resuscitation measures are successful. Critical Care    Vol 11 No 1    Spahn et al.
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The apparent weakness of much of the published evidence
cited in this work highlights the need for further clinical stud-
ies, and underlines the importance of future research that may
lead to more clear-cut evidence-based clinical guidelines. The
GRADE system employed in developing these guidelines [8]
is appropriate in that it allows strong recommendations to be
supported by weak clinical evidence in a field in which many of
the ideal randomised controlled clinical trials may never be
performed. Other systems, such as the grades of recommen-
dation developed by the Oxford Centre for Evidence-Based
Medicine [9], may be less dependent on the weight of expert
opinion, and therefore the process employed between the
published evidence and guideline recommendation must be
transparent in order to ensure acceptance and implementation
of the guideline. To minimise the bias introduced by individual
experts, this guideline employed a nominal group process to
develop each recommendation and several Delphi rounds to
reach an agreement on the questions to be considered and to
reach a final consensus on each recommendation, and the
group was composed of a multidisciplinary pan-European
group of experts, including the active involvement of repre-
sentatives from five of the most relevant European professional
societies.
Conclusion
We have made every effort to make these guidelines applica-
ble in daily practice in a variety of clinical settings. We wish to
emphasise our conviction that a multidisciplinary approach to
the management of the bleeding trauma patient will help cre-
ate circumstances in which optimal care can be provided. By
their very nature, these guidelines reflect the current state-of-
the-art and will need to be updated and revised regularly as
important new evidence becomes available.
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Key messages
￿  This guideline to clinical practice provides evidence-
based recommendations that were developed by a 
multidisciplinary task force with respect to many 
aspects of the acute management of the bleeding 
trauma patient and that when implemented may lead to 
improved patient outcomes.
￿  The time elapsed between injury and operation should 
be minimised for patients in need of urgent surgical 
bleeding control, and patients presenting with haemor-
rhagic shock and an identified source of bleeding 
should undergo immediate surgical bleeding control 
unless initial resuscitation measures are successful.
￿  Patients presenting with haemorrhagic shock and an 
unidentified source of bleeding should undergo immedi-
ate further assessment as appropriate using focused 
sonography, CT, serum lactate, and/or base deficit 
measurements.
￿  A damage control surgical approach is essential in the 
severely injured patient and may include the closure and 
stabilisation of pelvic ring disruptions, followed by 
appropriate angiographic embolisation or surgical 
bleeding control, including packing.
￿  This guideline also reviews appropriate physiological 
targets and suggested use and dosing of blood prod-
ucts, pharmacological agents, and coagulation factor 
replacement in the bleeding trauma patient.Available online http://ccforum.com/content/11/1/R17
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